TY - JOUR
T1 - Haemopoietic growth factors in the treatment of myelodysplastic syndrome
AU - Fra, Gian Paolo
AU - Avanzi, Gian Carlo
PY - 2006/11
Y1 - 2006/11
N2 - The myelodysplastic syndromes (MDS) are clonal stem cell disorders characterised by ineffective haematopoiesis, various degrees of cytopenia and risk of transformation to acute myelogenous leukaemia. The allogeneic haematopoietic stem cell transplantation (AHSCT) is the only potentially curative treatment for MDS; unfortunately, it can only be prescribed to a small percentage of patients. Although the high-risk group of patients are candidates for AHSCT, low-risk MDS patients are generally assigned to low-intensity therapies (e.g., supportive care, haematopoietic growth factors (HGF), biological response modifiers or immunosuppression) with the therapeutic goals to improve the cytopenias and to enhance the quality of life. Clinically available HGFs enable the stimulation of erythropoiesis, granulocytopoiesis and, with lesser efficacy, the megakaryocytopoiesis; however, they are not devoid of imperfections. This patent review focuses on the latest developments of new promising HGFs that could be significantly utilised in MDS.
AB - The myelodysplastic syndromes (MDS) are clonal stem cell disorders characterised by ineffective haematopoiesis, various degrees of cytopenia and risk of transformation to acute myelogenous leukaemia. The allogeneic haematopoietic stem cell transplantation (AHSCT) is the only potentially curative treatment for MDS; unfortunately, it can only be prescribed to a small percentage of patients. Although the high-risk group of patients are candidates for AHSCT, low-risk MDS patients are generally assigned to low-intensity therapies (e.g., supportive care, haematopoietic growth factors (HGF), biological response modifiers or immunosuppression) with the therapeutic goals to improve the cytopenias and to enhance the quality of life. Clinically available HGFs enable the stimulation of erythropoiesis, granulocytopoiesis and, with lesser efficacy, the megakaryocytopoiesis; however, they are not devoid of imperfections. This patent review focuses on the latest developments of new promising HGFs that could be significantly utilised in MDS.
KW - Darbepoetin-α
KW - Erythropoietin
KW - Granulocyte-colony stimulating factor
KW - Haemopoietic growth factors
KW - IL-11
KW - Myelodysplastic syndrome
KW - Thrombopoietin
UR - http://www.scopus.com/inward/record.url?scp=33751245845&partnerID=8YFLogxK
U2 - 10.1517/13543776.16.11.1557
DO - 10.1517/13543776.16.11.1557
M3 - Review article
SN - 1354-3776
VL - 16
SP - 1557
EP - 1568
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 11
ER -